Millennium Management’s Ventyx Biosciences VTYX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-989,917
| Closed | -$8.94M | – | 6450 |
|
|
2025
Q4 | $8.94M | Sell |
989,917
-661,877
| -40% | -$4.95M | ﹤0.01% | 2381 |
|
|
2025
Q3 | $5.14M | Buy |
1,651,794
+246,040
| +18% | +$652K | ﹤0.01% | 3128 |
|
|
2025
Q2 | $3.01M | Buy |
1,405,754
+1,179,444
| +521% | +$1.9M | ﹤0.01% | 3498 |
|
|
2025
Q1 | $260K | Sell |
226,310
-1,055,319
| -82% | -$1.81M | ﹤0.01% | 5171 |
|
|
2024
Q4 | $2.81M | Buy |
1,281,629
+1,008,760
| +370% | +$2.29M | ﹤0.01% | 3365 |
|
|
2024
Q3 | $595K | Sell |
272,869
-126,433
| -32% | -$291K | ﹤0.01% | 4693 |
|
|
2024
Q2 | $922K | Sell |
399,302
-73,364
| -16% | -$305K | ﹤0.01% | 4156 |
|
|
2024
Q1 | $2.6M | Sell |
472,666
-1,461,880
| -76% | -$6.68M | ﹤0.01% | 3494 |
|
|
2023
Q4 | $4.78M | Buy |
1,934,546
+1,875,786
| +3,192% | +$17.8M | ﹤0.01% | 2827 |
|
|
2023
Q3 | $2.04M | Buy |
58,760
+19,353
| +49% | +$669K | ﹤0.01% | 3530 |
|
|
2023
Q2 | $1.29M | Buy |
+39,407
| New | +$1.36M | ﹤0.01% | 3830 |
|
|
2023
Q1 | – | Sell |
-108,703
| Closed | -$4.23M | – | 6910 |
|
|
2022
Q4 | $3.56M | Buy |
108,703
+88,407
| +436% | +$2.62M | ﹤0.01% | 3085 |
|
|
2022
Q3 | $709K | Buy |
+20,296
| New | +$449K | ﹤0.01% | 4646 |
|
|
2022
Q2 | – | Sell |
-87,706
| Closed | -$1.19M | – | 7556 |
|
|
2022
Q1 | $1.19M | Sell |
87,706
-54,315
| -38% | -$726K | ﹤0.01% | 4367 |
|
|
2021
Q4 | $2.82M | Buy |
+142,021
| New | +$2.69M | ﹤0.01% | 3448 |
|
Other funds holding VTYX
Millennium Management's VTYX Position: Q1 2026 in Review
Millennium Management sold out of Ventyx Biosciences (VTYX) in Q1 2026, closing a stake of 989,917 shares — an estimated $8.94M sold.
Millennium Management first reported a position in VTYX in Q4 2021 and held it in 15 quarters. The position peaked at $8.94M in Q4 2025. 1 fund tracked by Wall St. Rank holds VTYX as of Q1 2026.
- Millennium Management reported no remaining Ventyx Biosciences position as of Q1 2026 after selling out during the quarter.
- Millennium Management sold 989,917 Ventyx Biosciences shares in Q1 2026, an estimated $8.94M.
- Millennium Management first reported a position in Ventyx Biosciences in Q4 2021 and held it in 15 quarters.
- Millennium Management's Ventyx Biosciences position peaked at $8.94M in Q4 2025.
- 1 fund tracked by Wall St. Rank held Ventyx Biosciences as of Q1 2026.
Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.